Abstract YO8
Case summary
Carcinosarcoma of the breast is an aggressive, malignant biphasic neoplasm. It is comprised of carcinomatous and sarcomatous elements and accounts for 0.08–0.2% of all breast malignancies. Due to the rarity of this disease, it remains poorly understood and infrequently reported. Here we present a case of a 38 year old Filipino woman with a 2 month history of mass in her left breast. Progressive enlargement of the mass warranted excisional biopsy and revealed high grade carcinoma. Metastatic work up were unremarkable. Thus, the patient underwent modified radical mastectomy. Histopathology revealed metaplastic carcinoma, carcinosarcoma type with background of ductal carcinoma in-situ, nuclear grade 1 with no definite lymphovascular space invasion. All 12 lymph nodes were negative for tumor but nipple was positive for tumor. Immunohistochemistry report revealed positive for ER, PR and negative for HER2/Neu overexpression. Furthermore, tumor cells were positive for pancytokeratin in carcinomatous areas and vimentin in sarcomatous areas. The patient is receiving hormonal therapy and remains to be asymptomatic and on close surveillance.
A multi-disciplinary approach with an accurate diagnosis are essential to optimally tailor potentially effective treatment options in this kind of patients. To date, there is no standardized treatment protocol for the management of carcinosarcoma of the breast. Long-term follow-up is important because of the increased likelihood of local recurrence and metastasis.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract